Depemokimab

Summary

Depemokimab (CHEMBL4650469) is a phase-3 clinical-stage antibody; indicated across 4 conditions including granulomatosis with polyangiitis and nasal cavity polyp.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650469
Name	Depemokimab
Type	Antibody
Max phase	3

Also known as: AQ-82742999, AQ82742999, Depemokimab, GSK-3511294, Gsk3511294, GSK3511294, DEPEMOKIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
granulomatosis with polyangiitis	3	MONDO:0012105	EFO:0005297
nasal cavity polyp	3	MONDO:0006314	EFO:1000391
hypereosinophilic syndrome	3	MONDO:0015691	EFO:1001467
asthma	3	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	13
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05263934	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05334368	PHASE3	RECRUITING	Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT06959095	PHASE3	RECRUITING	Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06961214	PHASE3	RECRUITING	Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06979323	PHASE3	RECRUITING	Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT07177339	PHASE3	RECRUITING	eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07456033	PHASE3	NOT_YET_RECRUITING	A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT04718103	PHASE3	COMPLETED	A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389	PHASE3	COMPLETED	A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04719832	PHASE3	COMPLETED	Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT05243680	PHASE3	COMPLETED	An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05274750	PHASE3	COMPLETED	Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
NCT05281523	PHASE3	COMPLETED	Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
NCT03287310	PHASE1	COMPLETED	First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
NCT05140200	PHASE1	COMPLETED	Study of GSK3511294 in Healthy Chinese Participants
NCT05602025	PHASE1	COMPLETED	A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).